We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cyramza

News List

FDA approves CYRAMZA® (ramucirumab) for EGFR-mutated non-small cell lung cancer europeanpharmaceuticalreview
June 02, 2020
CYRAMZA in combination with erlotinib was approved as a first-line treatment for metastatic EGFR-mutated non-small cell lung cancer.
Lilly secures FDA approval for Cyramza to treat liver cancer pharmaceutical-technology
May 15, 2019
Eli Lilly has obtained US Food and Drug Administration (FDA) approval for the use of its Cyramza (ramucirumab injection, 10mg/ml solution) as a monotherapy to treat hepatocellular carcinoma (HCC).
Lilly’s combo therapy succeeds in the late-stage lung cancer study expressbpd
March 19, 2019
Previously untreated patients with metastatic non-small cell lung cancer taking a combination of Lilly’s Cyramza and Roche’s erlotinib went longer before their disease started to worsen
Lilly’s combo therapy succeeds in late-stage lung cancer study expressbpd
March 13, 2019
Lung cancer is the leading cause of cancer death among both men and women, according to the American Cancer Society
Lilly and Sigilon partner to develop diabetes type I therapies pharmatimes
July 18, 2018
Eli Lilly and Sigilon Therapeutics have announced a global collaboration to develop encapsulated cell therapies for type I diabetes.